HUMAN ANTI ADALIMUMAB (DRUG/TARGET COMPLEX)

Human anti Adalimumab (drug/target complex), clone AbD20349_hIgG1, is an affinity matured, Type 3 antibody that specifically recognizes adalimumab complexed with TNFα. It does not recognize the free drug or unbound TNFα. Clone AbD20349_hIgG1 can be used in assays to measure adalimumab that has been captured via immobilized TNFα, thereby avoiding the bridging assay format. It can also be used to measure the level of the drug/target complex and biosimilar products using bioanalytical assays. Adalimumab (brand name Humira®) is a human monoclonal antibody (IgG1/kappa) approved for the treatment of rheumatoid, psoriatic and juvenile idiopathic arthritis, ankylosing spondylitis, Crohn’s disease and ulcerative colitis. This therapeutic antibody is directed against the pro-inflammatory cytokine tumor necrosis factor alpha (TNFα), blocking its interaction with the p55 (TNFR1, CD120a) and p75 (TNFR2, CD120b) cell surface TNF receptors, resulting in a down-regulation of the abnormal inflammatory response that is characteristic of autoimmune disease. View a summary of all anti-adalimumab antibodies.

• Clonality: Monoclonal
• Host: Human
• Isotype: IgG1

• Quantity: 0.1 mg
• Storage: +4ºC, -20ºC if preferred
• Buffer: Phosphate buffered saline, 0.01% Thiomersal

• ELISA (ELISA)